Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P150046/S005

Nevisense

Scibase AB · Decision date Feb 26, 2026

FDA DECISIONP150046/S005

What did the FDA approve?

FDA records P150046/S005 as a supplement to PMA P150046, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Feb 26, 2026.

FDA approval order statement

Approval for replacing the user manual text, Nevisense may only be used by dermatologists who have successfully completed the Nevisense training, with the following: Only dermatologists, who have completed Nevisense training, may initiate a Nevisense examination and utilize the Nevisense results in conjunction with other clinical parameters toobtain additional information prior to decision to biopsy. Nevisense may only be operated by healthcare professionals who have successfully completed the Nevisense training.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
General, Plastic Surgery
Decision date
Feb 26, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P150046/S005
Regulatory pathway
PMA supplement
Applicant
Scibase AB
Product code
ONV
Decision code
APPR
Decision date
Feb 26, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Electrical Impedance Spectrometer.

Applicant
Scibase AB
Product code
ONV
FDA device class
2

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P150046/S005 received

    Application receipt date recorded by FDA.

  2. P150046/S005 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P150046. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150046

Product / regulatory recordCompanyPathwayDecision dateSource
NevisenseP150046/S006
Scibase ABPMA supplementDec 15, 2025FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Scibase AB

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Kammakargatan 22, Stockholm, SE-1140

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records